RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced that the company has been awarded another metabolomics patent. The newly issued patent further expands the domain of previously issued patents to include multiple disease states related to nervous systems disorders including Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, depression and schizophrenia.
